Glad to hear it, Dave. Perhaps we're just beginning to see the value of Gerald's cutting-edge Stanford education. He mentioned in a prior interview that several of his classmates have founded successful, innovative companies of their own after graduation.

This is certainly a much different business model than the other biotech companies out there, but one that appears to have the potential to be highly lucrative for the company and its shareholders. This is most likely what attracted the talent that has joined the company. They see the future of this approach, even if most investors are taking longer to come around.